These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25703419)

  • 1. Use, efficacy and safety of prasugrel in patients with ST segment elevation myocardial infarction scheduled for primary percutaneous coronary intervention in clinical practice. Results of the prospective ATACS-registry.
    Zeymer U; Hochadel M; Lauer B; Kaul N; Wöhrle J; Andresen D; Schwimmbeck P; Solzbach U; Thiele H; Gitt A; Diller F; Zahn R
    Int J Cardiol; 2015 Apr; 184():122-127. PubMed ID: 25703419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
    Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
    Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
    Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
    Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
    JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Dimitroulis D; Golabkesh M; Naguib D; Knoop B; Dannenberg L; Helten C; Pöhl M; Jung C; Kelm M; Zeus T; Polzin A
    J Cardiovasc Pharmacol; 2018 Oct; 72(4):186-190. PubMed ID: 29985284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
    Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
    Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
    Bacquelin R; Oger E; Filippi E; Hacot JP; Auffret V; Le Guellec M; Coudert I; Castellant P; Moquet B; Druelles P; Rialan A; Rouault G; Boulanger B; Treuil J; Leurent G; Bedossa M; Boulmier D; Avez B; Gilard M; Le Breton H
    Arch Cardiovasc Dis; 2016 Jan; 109(1):31-8. PubMed ID: 26514325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
    Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
    Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
    Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
    JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
    Wang Z; Zhou DY; Su Y; Si LY; Xu Q
    BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
    Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
    Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
    JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary Antiplatelet Therapy and Clinical Outcomes of Japanese Patients With Acute Myocardial Infarction　- Results From the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).
    Yasuda S; Honda S; Takegami M; Nishihira K; Kojima S; Asaumi Y; Suzuki M; Kosuge M; Takahashi J; Sakata Y; Takayama M; Sumiyoshi T; Ogawa H; Kimura K;
    Circ J; 2019 Jul; 83(8):1633-1643. PubMed ID: 31204353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical review of prasugrel for formulary decision makers.
    Schafer JA; Kjesbo NK; Gleason PP
    J Manag Care Pharm; 2009 May; 15(4):335-43. PubMed ID: 19422273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Gill K; Servati N; Flahive J; Fraielli K
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):625-629. PubMed ID: 34236915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.